Opaleye reports 8.59% stake in Q32 Bio
Opaleye Management Inc., Opaleye, L.P. and James Silverman filed an amended Schedule 13G reporting shared beneficial ownership of 1,256,228 shares of Q32 Bio Inc. Common Stock, representing 8.59% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Opaleye Management Inc., Opaleye, L.P. and James Silverman filed an amended Schedule 13G reporting shared beneficial ownership of 1,256,228 shares of Q32 Bio Inc. Common Stock, representing 8.59% of the class. The filing states the interest is based on 14,629,463 shares outstanding as of March 1, 2026, as reported in Q32 Bio's Form 10-K. The statement explains the Fund directly holds the shares, the Adviser serves as investment adviser, and Mr. Silverman controls the Adviser; the joint filing agreement is included.
Key Figures
Key Terms
beneficially owned regulatory
Joint Filing Agreement regulatory
Schedule 13G/A regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Opaleye report in Q32 Bio (QTTB)?
Who are the reporting persons on the Schedule 13G/A for Q32 Bio?
Does the filing indicate sole voting or dispositive power for these holders?
What document confirms the joint reporting arrangement?
What CUSIP and class are reported for Q32 Bio in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.